Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (11)

2021

  1. Haemophagocytic syndrome and COVID-19

    Clinical Rheumatology, Vol. 40, Núm. 4, pp. 1233-1244

2018

  1. Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S121-S129

2017

  1. IgG4-Related Disease: Gastrointestinal Involvement

    Handbook of Systemic Autoimmune Diseases (Elsevier Ltd), pp. 399-410

2016

  1. Sarcoidosis: an update on current pharmacotherapy options and future directions

    Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 18, pp. 2431-2448

2015

  1. Etiopathogenic role of surfactant protein D in the clinical and immunological expression of primary sjögren syndrome

    Journal of Rheumatology, Vol. 42, Núm. 1, pp. 111-118

2012

  1. Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjögren's syndrome

    Clinical and Experimental Rheumatology, Vol. 30, Núm. 5, pp. 686-692

  2. Other biological therapies in primary Sjögren’s syndrome

    Sjogren's Syndrome: Diagnosis and Therapeutics (Springer-Verlag London Ltd), pp. 589-598

2011

  1. Rituximab therapy in lupus nephritis: Current clinical evidence

    Clinical Reviews in Allergy and Immunology, Vol. 40, Núm. 3, pp. 159-169

2010

  1. Bronchiectasis in primary Sjögren's syndrome: Prevalence and clinical significance

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 5, pp. 647-653

  2. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. [The importance of laboratory in the diagnosis in Sjogren's syndrome].

    Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina), Vol. 66, Núm. 1, pp. 14-30